- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 690KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 231KB)
Aflibercept – November 2024
Aflibercept (nAMD); Solution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL) pre-filled syringe; Eylea®
Last updated
30 May 2025